Yes, HIV affects stem cell eligibility, but it does not automatically exclude you from receiving a blood stem cell transplant. NIH guidance supports access for otherwise eligible people with HIV who need a transplant. Your team reviews HIV control, other infections, organ function, drug interactions, and the reason for treatment. Donating cells to someone else is a separate decision with stricter infection rules; a private clinic may also decline treatment under its own criteria. Special populations transplantation
This is general information. It is not personal medical advice.

Different Treatments, Different Rules
A blood stem cell transplant restores blood-forming cells after intensive chemotherapy or radiation. The cells can come from you (autologous), another person (allogeneic), or an identical twin (syngeneic). For cancer treatment, NCI lists eight suitability factors: cancer type and stage, whether your own cells can be used, donor availability, other treatment options, ability to tolerate high-dose chemotherapy, other serious health problems, and previous treatment. Stem cell transplant The distinction between autologous and allogeneic cells matters because using your own cells and receiving donor cells involve different eligibility questions.
Do not apply transplant eligibility rules to every injection advertised as stem cell therapy. FDA warns that unapproved regenerative products have caused infections, tumor formation, blindness, immune reactions, and cells growing in unintended locations. Those warnings concern unapproved products, not every cell treatment. Important patient and consumer information about regenerative medicine therapies
Approval is specific to a product and its indication. For example, FDA lists RYONCIL for steroid-refractory acute graft-versus-host disease in children aged two months and older. That approval does not establish eligibility for an unrelated clinic injection or show that it treats HIV. Ryoncil
Ask for the cell source, processing method, dose, route, intended use, and regulatory status. If the offer is a clinical trial, ask for its written inclusion and exclusion criteria and whether HIV is permitted. Acceptance by a clinic is not evidence that the treatment will benefit your condition.
What Your Medical Team Will Check
- HIV control: your antiretroviral therapy (ART), adherence, viral load, CD4 results, previous drug resistance, and any treatment interruptions. NIH recommends reviewing ART history, effectiveness, resistance, adherence, and drug interactions before transplant, and maintaining viral suppression before and after it. Good control alone does not qualify you for every procedure. Special populations transplantation
- Other infections and immunity: past opportunistic infections, tuberculosis, hepatitis B or C, any current fever or active infection, your vaccines, and your white blood cell counts. Transplant conditioning weakens immunity and raises infection risk. NCI names that risk as one of the main burdens of transplant. Stem cell transplant
- Organs and other conditions: your heart, lungs, liver, and kidneys, your blood counts and clotting, your blood sugar control, your cancer status, and any drugs you take that affect bleeding or immunity.
- Risk of that exact procedure: bone marrow collection, fat removal under anesthesia, an IV infusion, and a joint shot carry different infection, bleeding, and anesthesia risks. A joint shot and a transplant with weeks of immune suppression and hospital follow-up are judged by different standards.
Do not stop or change ART on your own to qualify for treatment. NIH warns that stopping ART after a blood stem cell transplant can cause serious viral rebound and recommends avoiding interruptions. If illness or inability to take medicines makes a change necessary, your HIV and transplant teams should manage it together. Bring your exact drug names, doses, schedule, and recent results. Special populations transplantation
When a clinic says HIV status does not matter at all, gives everyone the same protocol, or asks you to pause ART without calling your HIV doctor, slow down. Get a second medical opinion.
Donating Cells While Living With HIV
Having HIV generally prevents routine donation to another person under U.S. human cell and tissue product (HCT/P) donor-eligibility rules. These rules cover screening for HIV and testing for HIV-1 and HIV-2. However, they include limited provisions for use of cells from an ineligible donor, such as certain related-donor uses or a documented urgent medical need, with warnings, records, and physician notification. These are not a general permission to donate. Confirm the rules with the specific donor program, especially outside the United States. Subpart C
Using your own cells is different. Section 1271.90(a)(1) exempts cells and tissues for autologous use from that subpart's donor-eligibility determination and donor screening/testing requirements. This does not establish medical fitness or remove a hospital's or laboratory's own safety requirements. Ask which tests and handling arrangements apply to your proposed procedure. Subpart C
Confirm whether the proposed cells come from cord blood, peripheral blood, bone marrow, or fat. The cell source alone does not decide eligibility; the intended use and procedure also matter. For a Japan clinic enquiry, the treatment-process overview can help you identify which stages to ask about.
Viral Load and CD4 Requirements
Viral load measures HIV in the blood; CD4 results help assess immune status. Ask the treating program for its written requirements, the dates and units it needs, and whether it considers trends rather than one result. Do not use a cutoff from another clinic or a different transplant protocol as a personal clearance.
| Marker | What it shows | Why the team asks |
|---|---|---|
| Viral load | HIV level at the time of the test | How will viral suppression be maintained through treatment? |
| CD4 count and trend | One part of the immune assessment | Does this protocol have a CD4 requirement, and when should testing be repeated? |
| Infection history | Past or current opportunistic infections, tuberculosis, hepatitis B or C | Is infection treatment or prevention needed before proceeding? |
| Organ function | Kidney, liver, heart, and lung findings | Do the medicines or treatment plan need adjustment? |
Hospital Transplants and Clinic Injections Differ
People often mix three different stories together: a blood stem cell transplant for leukemia or lymphoma, a clinic shot sold for knees, back pain, or “rejuvenation,” and an experimental transplant studied in HIV cure research. These are separate things.
Hospital blood stem cell transplants
A transplant for blood cancer follows a hospital protocol. Allogeneic transplantation involves donor matching, conditioning treatment, and prolonged follow-up. NCI lists risks including infection, infertility, second cancers, and organ injury. With donor cells, graft-versus-host disease (GVHD) can occur when donor immune cells attack the recipient's tissues. Follow-up schedules depend on the transplant and complications; no single discharge date guarantees recovery. Stem cell transplant
Private clinic injections
An injection outside a blood stem cell transplant program should not be assumed to have either the same benefits or the same risk profile. Ask about the actual product rather than accepting a blanket claim of safety. FDA warns about contamination and serious harms from unapproved regenerative products, and says trial registration or FDA registration does not establish legal marketing. These are U.S. regulatory warnings, not a statement of Japanese law. Important patient and consumer information about regenerative medicine therapies
| Aspect | Hospital transplant | Clinic injection |
|---|---|---|
| Goal | Rebuild blood-making after intense cancer treatment | Depends on the marketing claim; often unproven for that use |
| Eligibility basis | Cancer indication, transplant fitness, HIV management; donor matching for allogeneic use | Exact product, intended use, clinic criteria, and laboratory acceptance |
| Treatment burden | Conditioning and prolonged specialist follow-up | Depends on the procedure; ask about collection, processing, and administration |
| Risk questions | How will infection risk, organ toxicity, and donor-cell GVHD be managed? | What product-specific safety evidence and contamination controls are available? |
A transplant result in leukemia says nothing about whether a joint shot helps arthritis. Neither says cell treatment treats HIV itself.
What About the Reported HIV Remissions
NIH guidance discusses HIV remission or cure after selected allogeneic blood stem cell transplants, including transplants using donors with the CCR5-delta32 variant. It also states that blood stem cell transplantation is standard care for people with HIV when indicated for a blood cancer. That is not a recommendation to undergo a transplant for HIV alone or to buy an unrelated cell injection. Special populations transplantation
A transplant remission report is not evidence that a routine injection cures HIV. Ask for evidence for the exact product, route, and patient group. A study registry entry alone does not establish safety or benefit.
When someone outside a qualified transplant center and outside a properly overseen protocol offers you a “cure,” ask for the exact protocol, the oversight body, the published results for that product and that patient group, and the long-term follow-up plan. Get the answers in writing.
For routine HIV care, ART remains the established treatment. WHO explains that antiretroviral drugs stop HIV from replicating but do not cure the infection. Rare transplant remission reports do not change the need to take your prescribed ART. Hiv aids
How Eligibility Screening Works in Japan
If you are considering a clinic in Japan, ask for its written HIV policy before booking travel or paying for treatment. Does it exclude people with HIV, assess them individually, or require review by another specialist? Ask the same question about the processing laboratory. The clinic's published safety information and indications and contraindications overview can help frame these questions, but they are not independent medical evidence or confirmation of your eligibility. Ask separately for the regulatory status and evidence for the exact intended use; do not treat a filed plan as proof of efficacy.
Bring a short file to your first review: your HIV diagnosis year, your ART history, recent viral load and CD4 dates and values, resistance testing if you have it, hepatitis B and C results, tuberculosis history, current drugs and allergies, heart, lung, liver, and kidney diagnoses, past cancers and their treatment, bleeding history, and the exact cell procedure you are asking about. Also ask which tests the clinic repeats locally, how old a result can be, and whether reports from abroad need translation.
Questions to Ask Any Provider
When comparing stem cell hospitals in Japan, request written answers to these questions:
- What exact procedure are you suggesting for my diagnosis, and what is its regulatory status for that use?
- Are you assessing me as a recipient, as a donor, or both — and which infection tests apply to my path?
- Do you require a certain viral load, CD4 level, ART stability, or infection-free period, and why?
- How will you work with my HIV doctor, and what happens to my ART around collection, conditioning, or anesthesia?
- Who processes the cells, and does that lab accept samples from people living with HIV?
- What are the product-specific risks, the likely benefits, the proven alternatives, the follow-up plan, and the full cost?
- What would delay or cancel treatment, and who makes the final eligibility call?
A clear provider names the test, explains why you need it, and tells you what happens with an abnormal result.
For a practical first enquiry, prepare a one-page medication list and copies of your lab reports with dates, units, and reference ranges. Ask: “Can your physician review these records before I travel, which tests would need repeating, and does your laboratory accept my proposed sample?” This is a preparation checklist, not a report of patient outcomes or a promise of acceptance.
Bottom Line
HIV does not automatically rule out receiving a medically indicated blood stem cell transplant. The decision belongs with the transplant and HIV teams. It is separate from donor eligibility and from a private clinic's acceptance policy. Keep ART decisions with your treating clinicians, and ask for written criteria for the exact procedure rather than relying on a generic yes-or-no answer. Special populations transplantation
General information only. The treating physician makes the final eligibility call after reviewing your records, your exam, and your lab results.
Unsure where your HIV records fit in the screening?
Bring your recent viral load and CD4 results, and ask what the first medical review checks before any procedure is scheduled.
References
- NIH, Transplantation in People With HIV. U.S. clinical guidance: equitable access, HIV management, drug interactions, ART continuity, and blood stem cell transplantation. Reviewed 2026-11-02.
- National Cancer Institute, Stem Cell Transplants in Cancer Treatment. U.S. cancer-treatment context: transplant types, suitability factors, conditioning, and risks. Accessed 2026-11-01.
- FDA, Important Patient and Consumer Information About Regenerative Medicine Therapies. U.S. warnings about unapproved products and registration claims; page dated 8 April 2024. Accessed 2026-11-01.
- FDA, RYONCIL. U.S. product indication: steroid-refractory acute GVHD in pediatric patients aged two months and older; page dated 17 January 2025. Accessed 2026-11-02.
- eCFR, 21 CFR Part 1271, Subpart C. U.S. HCT/P donor rules, including §§1271.65 and 1271.90 exceptions. Accessed 2026-11-01; relevant exceptions reviewed 2026-11-02.
- WHO, HIV and AIDS. Global public-health context: ART suppresses HIV but does not cure infection. Accessed 2026-11-01.




